depression

9511213674_31a3c06cc7_z

Introduction

Clinical, unipolar depression is more than just feeling low for a day or two.

Depression is characterised as episodes of sadness, loss of interest and pleasure, often including feelings of low self-worth. Depression can also include a range of physiological symptoms, such as fatigue, pain, diminished appetite, lack of interest in sex, disturbed sleep, and poor concentration.

The World Health Organisation estimates that, globally, as many as 350 million people are affected at any given time, with one person in 20 reporting an episode of depression in a 12 month period (in a global sample of 17 countries). They describe depression as the leading cause of disability worldwide.

What we know already

We know that, despite the considerable global burden of depression, not everybody receives treatment, with figures ranging from 50% to 10% in less developed countries.

Evidence suggests that combined psychological and pharmacological treatments seem to work well. Broadly, we know that psychotherapies work in many cases – but not every time. We know that neurochemical factors, such as serotonergic dysfunction, play an important role in depression, which goes a long way in explaining the efficacy of SSRI treatments.

We also know that depression has a nasty habit of recurrence, and some psychological interventions, such as Mindfulness-Based Cognitive Therapy (MBCT) is recommended particularly for people who have experienced multiple episodes of depression, but not are currently severely depressed.

We know that people living with chronic physical illness are more likely to experience depression, and this combination is linked with poorer clinical outcomes.

Importantly though, we know that people with depression can still enjoy themselves, and a common misconception in depression is that people feel totally awful all of the time.

Areas of uncertainty

There is much still to determine. For example, we know that depression is hereditable, however the extent of heredity versus environmental influences are unclear.

We are also unsure as to the precise mechanisms that determine those who respond best to treatments, be they psychopharmacological, or psychological, or both.

What’s in the pipeline?

Despite advances in our understanding of depression, and how it is treated, it remains a highly recurrent difficulty, with many people not achieving complete remission between episodes.

Preventative interventions, either physiological, or psychological, may improve people’s resilience to depression, particularly those identified as being highly prone.

References

Cuijpers, P. (2015). Psychotherapies for adult depression: recent developments. Current Opinion in Psychiatry, 28, 24-29. [Abstract]

Naylor, C., Parsonage, M., McDaid, D., Knapp, M., Fossey, M. and Galea, A. (2012) Long-term conditions and mental health: the cost of co-morbidities. The King’s Fund, London, UK [PDF]

World Health Organisation (2015).Factsheet 369: Depression [Link]

Photo Credits

Sascha Kohlmann CC BY 2.0

Acknowledgement

Written by: Patrick Kennedy-Williams
Reviewed by:
Last updated: Nov 2015
Review due: Sep 2016

Our depression Blogs

IPT and CBT best for depression in children and young people, says network meta-analysis

4929686071_970be30b8d_o

Laura Hemming summarises a recent network meta-analysis of psychotherapies for depression in children and young people, which finds that Interpersonal Psychotherapy (IPT) and Cognitive Behavioural Therapy (CBT) were significantly more efficacious than other psychotherapies at post-treatment and follow-up.

[read the full story...]

Work Capability Assessments linked with increase in suicides

13903379060_65bd06a926_k

Ian Cummins considers the findings of a recent longitudinal study that measures the impact that welfare reform and disability assessments have had on mental illness and rates of suicide.

[read the full story...]

All in the mindfulness? Reflections on the Mindful Nation report

5259784851_6708fc11b5_b

André Tomlin considers the recommendations for health service delivery and research from the recent Mindful Nation report.

[read the full story...]

Cognitive behavioural prevention of depression in adolescents

Higher levels of cortisol were associated with higher levels of depression

Emily Stapley summarises a recent RCT of a cognitive behavioural prevention programme for young people at risk of depression.

[read the full story...]

Computerised CBT for depression is no better than usual GP care: the REEACT trial

Last November we blogged the REEACT trial and concluded that computerised CBT for depression is no better than usual GP care.

Another debut blog today, this time from Suzanne Dash, who presents the results of the REEACT trial published last week in the BMJ. The study found limited uptake of computerised CBT by people with clinical depression and no benefit of free or commercially available cCBT packages over usual GP care.

[read the full story...]

Antidepressants vs placebo for depression: forget the gap

566200801_89ede04e1f_b

Ioana Cristea considers the possible causes responsible for the apparent narrowing of the drug-placebo gap, which over the last 30 years has seen estimates of depression symptom reduction from antidepressants fall from 70% to 30%.

[read the full story...]

Is cCBT doing it for the kids, but not the adults?

7085307427_d35f27907c_k

Karina Lovell appraises the first UK RCT of computerised cognitive behavioural therapy (cCBT) for depression in children and young people, which shows a clinically meaningful improvement in depression and anxiety.

[read the full story...]

Should we recommend CBT for depression in people with learning disabilities?

CBT

Leen Vereenooghe summarises a systematic review of the use of CBT (cognitive behavioural therapy) to treat depression in people with learning disabilities.

[read the full story...]

Placebo responding and µ-opioid brain functioning predict efficiency of antidepressants

259502894_f3e435ebd8_o

Dan-Mikael Ellingsen explores the neurochemistry of placebo effects in major depression, as he reviews a recent study of the association between placebo-activated neural systems and antidepressant responses.

[read the full story...]